We find that (1) BRAFi treatment is associated with DNFA stimulation in a dose-response relationship and (2) elevated DNFA gene expression is a vital survival trait of melanoma cells both before and after they achieve resistance to combined BRAF/MEK inhibition. The gene discussed is MAP2K7; the disease is melanoma.